Mirtazapine for Appetite Support: Nausea-First and Interaction Boundary

Mirtazapine may support appetite in selected dogs or cats, but nausea, pain, obstruction, oral disease, diet, organ function, and serotonergic interactions need attention first.

This prescription medicine affects several neurotransmitter receptors and may be used orally or in a species-specific veterinary transdermal context. Formulations, exposure, and handling instructions differ.

A veterinarian may discuss it when reduced intake persists after likely causes such as nausea or pain are addressed and when stimulating interest in food fits the broader nutrition plan.

A symptom-control plan may protect comfort, hydration, nutrition, sleep, mobility, and treatment continuity while the team also investigates the cause. Success means a defined improvement in the patient’s function or comfort, not simply suppressing a warning sign.

The prescriber considers the suspected cause, severity, organ function, cancer treatment, comorbidities, all medicines and supplements, previous reactions, and what can safely be managed at home. Families need written start, stop, missed-dose, and escalation instructions.

AAHA oncology and veterinary pharmacology sources include mirtazapine among appetite-support options. Evidence is stronger for some species and conditions than others, and increased food-seeking does not prove adequate calories, nutrition balance, or tumor benefit.

Agitation, vocalization, sedation, gastrointestinal effects, blood pressure or heart-rate changes, serotonin toxicity, and prolonged exposure with liver or kidney disease are considerations. Accidental caregiver exposure to topical product requires prevention.

Do not use another pet’s or a person’s medicine, combine products, repeat a vomited dose, or alter a prescription without instructions. Severe weakness, collapse, breathing difficulty, uncontrolled pain, repeated vomiting, inability to urinate, major bleeding, or rapid deterioration warrants urgent assessment.